



Medicine Manufacturing  
Industry Partnership



## MMIP Latest Update: July 2016

This is the latest update from the Medicines Manufacturing Industry Partnership. If you have any feedback on the content or information here then please email us at [MMIP@bioindustry.org](mailto:MMIP@bioindustry.org). If you have any colleagues you feel would be interested in learning more about the work of MMIP then please ask them to get in touch with us or [sign up to our mailing list here](#).

### Manufacturing output data

Recent data from the [ONS UK Index of Production](#) shows that pharmaceutical manufacturing saw an 8.6% rise in April 2016, it's largest rise since July 2012. However, the latest data shows a decrease of 6.5%. The overall increase is understood to be caused by increased exports. Work is ongoing to better understand the UK pharmaceutical sector's footprint, the causes of the volatility and what can be done to ensure the UK medicines manufacturing sector continues to thrive in the future.

### Advanced Therapies Manufacturing Taskforce update

The Advanced Therapies Manufacturing Taskforce held its second meeting of three on Tuesday 28 June. Since the last meeting each of the three workstreams (International Competitiveness, Skills and People, Manufacturing and Technology) have held workshops and other engagement activity to develop a series of prioritised actions for the Taskforce meeting to consider. Work is in progress to ensure buy-in from relevant stakeholders and Government departments. The final meeting will take place in November.

### New ABPI Head of Manufacturing Innovation

The ABPI has recently appointed a new Head of Manufacturing Innovation. Dr Magda Papadaki joins from Innovate UK where she was Lead Technologist for the Regenerative Medicine program. She is a trained stem cell and gene therapy scientist and has over a decade of experience in research, with regulatory and business experience in the EU and US.

She joins the rest of the MMIP operational team including Neil Baker from Pfizer, Gregor Anderson from GSK, Ian Dick from GSK and David Garton from AstraZeneca.



Magda Papadaki (ABPI) with MMIP Industry operational team (from left to right): Neil Baker (Pfizer), Greg Anderson (GSK), Ian Dick (GSK) and David Garton (AZ)

### **Open Funding calls from Innovate UK and H2020**

The KTN MedBio team has produced a blog highlighting a number of [Innovate UK funding calls](#) which are relevant to the sector. If you are interested and would like support to apply for any of these opportunities then please contact Mark Bustard at the KTN ([mark.bustard@ktn-uk.org](mailto:mark.bustard@ktn-uk.org)).

### **MHRA Innovation Office supports Queen's University Belfast**

Queen's University Belfast has been developing novel patches that are showing considerable promise as an effective and safe platform for transdermal drug delivery, as well as for minimally-invasive patient monitoring/diagnosis. MHRA Innovation Office's [latest case study](#), looks at how they helped QUB in preparing for the regulatory framework that will be the final step in bringing innovation to market.

### **Consultations**

- **MHRA consultation on guidance for medical devices**

The Medicines and Healthcare products Regulatory Agency is asking for comments on its [draft guidance for medicinal devices](#). This guidance is intended to be a useful resource on human factors and usability engineering principles, to clarify the expectations of the regulatory bodies. It is aimed at manufacturers of all device classes who intend to market their device in the UK. The consultation closes on 5 August.

- **IMI consultation on advanced therapies**

IMI has developed a [concept paper on advanced therapies](#). The aim of the concept paper is to identify the potential of IMI as a platform for enhancing ATMP research and development. The deadline for submitting comments is 25 July 2016.

- **GMP guideline for ATMPs**

The European Commission Directorate General for Health and Food Safety has launched a [consultation on draft guidelines of good manufacturing practice for ATMPs](#). The consultation runs until 26 September 2016.

I hope you find this note of interest and we will continue to communicate and create a community of committed likeminded professionals who can help with MMIP. Please contact us at [MMIP@bioindustry.org](mailto:MMIP@bioindustry.org) or join our LinkedIn group at [http://bia.me/MMIP\\_LinkedIn](http://bia.me/MMIP_LinkedIn). Likewise, if you have any colleagues you feel would be interested in learning more about the work of MMIP then please ask them to get in touch with us or [sign up to our mailing list here](#).

Ian McCubbin

Chairman, Medicines Manufacturing Industry Partnership

